Furopath-CV 625 Tablets – Cefuroxime Axetil 500mg + Clavulanic Acid 125mg Antibi

Furopath-CV 625 Tablets combine Cefuroxime Axetil 500 mg and Clavulanic Acid 125 mg to provide broad-spectrum antibacterial coverage for resistant and mixed bacterial infections. This dual-action formulation enhances efficacy against β-lactamase–producing organisms, ensuring reliable and effective treatment.

Cefuroxime, a second-generation cephalosporin, inhibits bacterial cell wall synthesis, while Clavulanic Acid protects it from enzymatic degradation, restoring its activity against resistant strains. The combination offers predictable absorption, strong bactericidal action, and good tolerability.

Key Benefits

• Broad Gram-positive and Gram-negative coverage
• Effective against β-lactamase–producing bacteria
• Proven bactericidal activity
• Suitable for mixed and resistant infections
• Good tolerability profile
• Convenient oral administration

Indications

• Respiratory tract infections
• Urinary tract infections
• Skin and soft tissue infections
• ENT infections
• Community-acquired infections